PMH28: THE IMPACT OF UNRECOGNIZED BIPOLAR DISORDERS FOR PATIENTS TREATED WITH ANTIDEPRESSANT MEDICATIONS  by Thiebaud, P et al.
352 Abstracts
PMH26
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OBJECTIVES: Atypical antipsychotics (AA) (e.g., olan-
zapine, risperidone) in combination with mood stabiliz-
ers (MS) (e.g., lithium, valproate) have demonstrated
better treatment response in acute bipolar mania com-
pared with MS monotherapy, and may be better tolerated
than conventional antipsychotics (e.g., haloperidol).
However, their acquisition costs are relatively high. The
objective of this study was to assess the cost-effectiveness
of AA in combination with MS in acute bipolar mania.
METHODS: We developed a state-transition Markov
model to estimate the cost-effectiveness of combination
therapy with AA + MS in acute bipolar mania. The incep-
tion cohort consists of patients hospitalized with a new
episode of acute mania. Each patient may receive: olan-
zapine + MS, risperidone + MS, haloperidol + MS, lithium
monotherapy, or valproate monotherapy as initial
therapy. Over subsequent 3-week cycles, patients initiated
on each therapy may remain manic, become depressed,
die from suicide or other causes, or stabilize and enter the
continuation/maintenance phase of treatment. While in
each health state, patients accumulate medical-care costs
(for drugs, hospitalization, etc.) and utility associated
with that state. The model tracks patients’ state transi-
tions over 24 weeks and tabulates cumulative costs and
utilities over the patients’ lifetime (discounted at an
annual rate of 3%) to estimate incremental cost per
quality-adjusted life-year (QALY) gained. Transition
probabilities between states were estimated from pub-
lished literature; costs were derived from standard
sources; utilities were assessed using the standard gamble
method. RESULTS: Haloperidol + MS is the least costly
therapy option, while risperidone + MS is the most effec-
tive. Risperidone + MS costs an additional $3300, and
olanzapine + MS an additional $8700, per QALY gained
versus haloperidol + MS. Both AA + MS combinations
were cost saving versus monotherapy with lithium or val-
proate. Results were sensitive to drug costs, drug efﬁcacy,
suicide rate, and rate of tardive dyskinesia. CONCLU-
SIONS: Based on current evidence, combination therapy
with AA + MS is cost-effective versus haloperidol + MS
in the treatment of acute mania, and dominates MS
monotherapy.
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OBJECTIVE: To measure effects on mental and other
healthcare expenses of family members of patients with
bipolar disorder, schizophrenia, and major depression.
METHODS: Using data from a 2-million member health
plan, the authors estimated and compared expenses for
mental and other healthcare services per person per
month (PPM) of family members of patients with bipolar
disorder, schizophrenia, and major depressive disorder
with those of controls. Ordinary least squares and logis-
tic regression models were used to estimate differences
and identify characteristics affecting healthcare expenses
within each group. RESULTS: Living with patients with
bipolar disorder, schizophrenia, or major depression
increased both mental and other healthcare expenses 
for family members, compared with controls. Mental and
other healthcare expenses increased as follows: bipolar
disorder, $8.85/PPM (213%; P < 0.0001) and $10.65/
PPM (7.4%; P < 0.0001); schizophrenia, $4.03/PPM
(81%; P < 0.0001) and $5.96/PPM (4.2%; P < 0.005);
major depression, $8.24/PPM (219%; P < 0.0001) and
$9.46 (6.5%; P < 0.0001). Within all three groups, men
were less likely to use mental healthcare services (P <
0.002), and the likelihood of mental healthcare use
increased with illness duration (P < 0.005). Within the
bipolar and major depression groups, parents and
spouses of patients were more likely to use mental health-
care services than children and siblings (P < 0.0001), and
the likelihood of mental healthcare use increased with
illness severity (P < 0.0001). Within all three groups,
other healthcare expenses were higher for parents and
spouses of patients (P < 0.0001–P < 0.01) and with longer
illness duration (P < 0.0001–P < 0.0005); men had lower
expenses (P < 0.0001–P < 0.05). Within the bipolar 
and major depression groups, other healthcare expenses
were higher for family members of older patients (P <
0.0001–P < 0.003). CONCLUSION: Living with a
person with serious mental illness signiﬁcantly increases
healthcare expenses of family members, especially for
mental healthcare. Family members of patients with
bipolar and major depressive disorders have higher
healthcare expenses than those of patients with schizo-
phrenia among commercially insured persons.
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OBJECTIVES: Patients with unrecognized bipolar disor-
ders (UBP) are often treated for depression prior to being
correctly diagnosed, thus delaying appropriate drug
therapy. This study compared hospital use, attempted 
suicides and one-year post-treatment costs of UBP
patients relative to patients with major depressive dis-
orders (MDD) and recognized bipolar (RBP) patients.
METHODS: Data from the California Medicaid program
for the period October 1994 to January 1999 were used
to identify 25,308 adult patients who initiated a new
episode of antidepressant therapy. RBP patients received
their initial diagnosis of bipolar disorders or used mood
stabilizers on or before the initiation of antidepressant
therapy. UBP patients initiated antidepressant therapy
with an initial MDD diagnosis, then received a bipolar
disorder diagnosis or initiated mood stabilizer therapy at
a later date. Multivariate models were used to estimate
the marginal risks and costs associated with UBP patients
relative to RBP or MDD-only patients. RESULTS: RBP
and UBP patients represented 15.4% and 6.3% of all
antidepressant users, respectively. UBP patients had
higher rates of hospital use (12.5%) and attempted
suicide (0.88%) than RBP patients (11.2% and 0.29%)
or MDD patients (7.5% and 0.18%). Multivariate results
indicated that UBP patients were three times more likely
to use hospital services (p < 0.0001) and 3.2 times more
likely to attempt suicide (p = 0.0004) than MDD patients.
RBP patients were twice as likely to use hospital care (p
< 0.0001) than MDD patients. UBP was associated with
higher 1-year outpatient costs relative to RBP patients
(+$200; p < 0.05), but was not associated with higher
inpatient or total costs. RBP was associated with lower
one-year outpatient costs ($109; p < 0.05) but higher
inpatient costs ($634; p < 0.001) and total costs ($508;
p < 0.01) relative to MDD patients. CONCLUSIONS:
UBP is both common and costly. More effort is needed to
provide early and correct diagnosis, and to effectively
treat these patients.
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ECONOMIC BURDEN OF NOT RECOGNIZING
BIPOLAR DISORDER PATIENTS
Birnbaum HG1, Dial E1, Oster EF1, Greenberg PE1, Shi L2
1Analysis Group/Economics, Boston, MA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVE: This study compared treatment patterns
and costs for bipolar disorder (BP) patients (recognized
and unrecognized) to those of major depression disorder
(MDD) patients without a BP claim (non-BP) during the
observational period. METHODS: An employer claims
database (1998–2001) was used to identify 9009 patients
(aged 18–65) diagnosed with MDD and initially treated
with antidepressants (AD). A subset of patients was iden-
tiﬁed as bipolar based on a BP diagnosis claim and/or a
mood stabilizer claim. Of these BP patients, unrecognized
BP (UBP) patients received their initial BP diagnosis
and/or mood stabilizer (MS) prescription after AD initi-
ation, while recognized BP (RBP) patients had these
records on/before AD initiation. Medical costs are total
payments to providers; indirect costs are payments to
employees for lost work time. RESULTS: BP patients
accounted for 7.0% of the research sample (3.7% UBP,
3.3% RBP). UBP patients incurred signiﬁcantly more
monthly medical costs in the 12 months following initia-
tion of AD treatment than RBP patients, for both non-BP
treatment costs ($1081 versus $683) and total medical
costs ($1179 versus $802). MDD total medical costs
($585) were signiﬁcantly lower than both RBP and UBP
costs. In the 6 months before the Index Date, UBP and
RBP patient monthly costs for medical care other than BP
treatment were similar ($542 versus $504, respectively).
MDD total medical costs ($436) were signiﬁcantly lower
than RBP total costs ($631), but not UBP total costs
($542). Monthly indirect costs are signiﬁcantly greater for
UBP and RBP employees compared to MDD employees
in the 12 months following the Index Date ($570, $514,
and $335, respectively). CONCLUSIONS: Accurate and
timely recognition of BP disease is associated with lower
overall medical costs and lower indirect work loss costs.
More effort is needed to quickly diagnose and effectively
treat patients with bipolar disorder.
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OBJECTIVE: To compare the mental health resource use
associated with risperidone, olanzapine, and quetiapine
for treatment of bipolar disorder in a real-world setting.
METHODS: This was a retrospective, comparative study
based on claims data compiled from several US health
plans from 1999 to early 2002. Antipsychotic treatment
episodes were constructed to more accurately identify
mental health resources associated with risperidone, 
olanzapine, and quetiapine. Selection bias was reduced 
by focusing only on episodes involving antipsychotic
monotherapy and for which the patient did not switch
from a prior antipsychotic. The primary measure ana-
lyzed was non-antipsychotic mental health care charges
per patient per month (PPM), deﬁned as total mental
health care charges excluding antipsychotic drug charges
during treatment episodes with risperidone, olanzapine,
or quetiapine. To control for differences in patient 
characteristics, regression models combining risperidone,
olanzapine, and quetiapine treatment episodes were esti-
mated to determine their effects on non-antipsychotic
mental health resource use. RESULTS: Regression esti-
mates showed that quetiapine was associated with the
lowest non-antipsychotic mental health care charges
